Effect of osimertinib in treating patients with first-generation EGFR-TKI-resistant advanced non-small cell lung cancer and prognostic analysis

Yang, YL; Guo, Y; Wang, R; Li, J; Zhu, HB; Tian, RF; Guo, W

Guo, W (corresponding author), Shanxi Prov Canc Hosp, Dept Resp, 3 Zhigongxinjie, Taiyuan 030001, Shanxi, Peoples R China.

JOURNAL OF BUON, 2021; 26 (1): 51

Abstract

Purpose: To explore the efficacy and safety of the third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Osimertinib ......

Full Text Link